Document is current
Any future updates will be listed below
-
Authors
Cerezo-Martín, Juan Manuel https://orcid.org/0000-0001-8049-6787
Yañez, Lucrecia
Colorado, Mercedes
Salas, María Queralt https://orcid.org/0000-0003-4567-3682
Pérez-López, Estefanía
Martín-Sánchez, Guillermo https://orcid.org/0009-0001-7408-0926
Fernández-Escalada, Noemí
España, Lucia https://orcid.org/0009-0001-7062-0569
Basalobre, Pascual
López-Corral, Lucía https://orcid.org/0000-0003-1908-5596
Rovira, Montserrat
Bermúdez, M. Aránzazu
,
-
Funding
Funding for this research was provided by:
This work was funded by the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC; https://www.geth.es/) and was partially supported by a grant from GEBRO Pharma SA, Spain
- License Information
-
More Information
Article History
Received: 29 September 2025
Revised: 6 December 2025
Accepted: 9 February 2026
First Online: 25 February 2026
Competing interests
: This work was funded by the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC; ) and was partially supported by a grant from GEBRO Pharma SA, Spain.
: The study was conducted in accordance with the seventh revision of the Declaration of Helsinki (Fortaleza, Brasil 2013), in effect when approval was obtained from the Independent Review Board (CEIm Cantabria under study code 2022.179). All participants still alive provided written informed consent before any investigational procedure was made. The IRB granted an exemption from informed consent for those patients who had died at the time of data review.
